Chinese vaccine makers sign Covax agreements for 500 million doses

Covax is an UN-backed program that aims to deliver vaccines to poor countries and others that need them.

Covaxin has started trials on children; it would be for children who are two years or older
AP Beijing
1 min read Last Updated : Jul 12 2021 | 8:49 PM IST

China's two major COVID-19 vaccine makers have signed agreements to provide up to 550 million doses to COVAX, the UN-backed program that aims to deliver vaccines to poor countries and others that need them.

Gavi, the vaccine partnership playing a leading role in COVAX, announced that it would buy 110 million doses from Sinopharm and Sinovac between now and October. In addition, it has the option to buy 440 million more doses by mid-2022.

The World Health Organization has approved the companies' vaccines for emergency use. Their inactivated vaccines are already in widespread use in China and in many other countries.

Inactivated vaccines are made with killed coronavirus. Most other COVID vaccines in use, particularly in the West, are made with newer technologies that target the spike protein that coats the surface of the virus.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jul 12 2021 | 8:49 PM IST

Next Story